8-K: OrthoPediatrics Corp. Investor Presentation Highlights Growth and Strategic Acquisitions

OrthoPediatrics Corp. outlines its strategic focus on pediatric orthopedics, highlighting consistent growth, innovative product development, and recent acquisitions in a new investor presentation.

Summary

• OrthoPediatrics is a company focused exclusively on pediatric orthopedics, addressing the unique needs of children with specialized products and services.
• The company has experienced consistent growth since its inception, with a 20%+ growth rate excluding the COVID-impacted year of 2020.
• OrthoPediatrics has a broad portfolio of 71 unique pediatric systems and continues to launch innovative products.
• The company has expanded its market reach through strategic acquisitions, including Boston Orthotics & Prosthetics, MD Orthopaedics, and Pega Medical.
• OrthoPediatrics is committed to clinical education, sponsoring medical societies and conducting over 300 clinical product/education events annually.
• The company's total global addressable market is estimated at $5.0 billion, with a current global target market of $2.8 billion.
• The U.S. current target market is estimated at $1.2 billion, with a potential U.S. market of $1.0 billion for specialty bracing.
• OrthoPediatrics has a strong history of year-over-year growth, with 2023 revenue reaching $148.7 million and a 2024 revenue guidance of $200 to $203 million.
• The company's revenue is primarily driven by trauma and deformity products, followed by scoliosis and sports medicine.
• First quarter 2024 revenue was $44.7 million, a 41% increase compared to the same period in 2023.
• Adjusted EBITDA for the first quarter of 2024 was a loss of $1.1 million, compared to a loss of $2.1 million in the first quarter of 2023.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong growth and strategic acquisitions, but also acknowledges risks and losses, resulting in a moderately positive sentiment.

Positives

• OrthoPediatrics is uniquely positioned as the only company focused solely on pediatric orthopedics.
• The company has a proven track record of consistent growth, with a 20%+ growth rate since inception, excluding 2020.
• OrthoPediatrics has a broad and innovative product portfolio, with 71 unique pediatric systems.
• Strategic acquisitions have expanded the company's market reach and product offerings.
• The company is committed to clinical education, fostering relationships with surgeons and driving sustainable growth.
• The company has a large addressable market with significant growth potential.
• OrthoPediatrics has a strong history of year-over-year revenue growth.
• The company's first quarter 2024 revenue shows a significant increase of 41% compared to the same period in 2023.

Negatives

• The company reported an operating loss of $9.7 million for the first quarter of 2024.
• The company reported a net loss of $7.8 million for the first quarter of 2024.
• Adjusted EBITDA for the first quarter of 2024 was a loss of $1.1 million.
• The company's adjusted loss per share for the first quarter of 2024 was $0.30.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the impact of health emergencies.
• OrthoPediatrics' ability to achieve or sustain profitability in the future is not guaranteed.
• The company may need to raise additional capital to fund operations and growth.
• There is a risk that the company may not be able to commercialize new products effectively.
• The company is subject to extensive government regulation and oversight.
• OrthoPediatrics faces competition from larger companies that repurpose adult implants for pediatric use.
• The company's non-GAAP financial measures have limitations and may not be comparable to other companies.

Future Outlook

OrthoPediatrics anticipates revenue between $200 and $203 million and adjusted EBITDA between $8.0 and $9.0 million for the full year 2024. The company expects continued growth through product innovation, strategic acquisitions, and market expansion.

Management Comments

• Management believes that providing non-GAAP diluted loss per share excluding certain expenses assists investors because such expenses are not reflective of ongoing operating results.
• Management uses adjusted EBITDA as a measure of the company's operating performance and for planning purposes.
• Management estimates the total global addressable market at $5.0 billion.
• Management estimates the U.S. current target market at $1.2 billion.
• Management estimates the U.S. specialty bracing market at $0.5 billion.

Industry Context

OrthoPediatrics operates in the pediatric orthopedics market, which is characterized by a lack of specialized solutions and a reliance on repurposed adult implants. The company's focus on pediatric-specific products and clinical education positions it to capture a significant share of this market. The acquisitions of companies like Boston Orthotics & Prosthetics and Pega Medical demonstrate a strategy to expand into related areas and offer a broader range of solutions for pediatric patients.

Comparison to Industry Standards

• OrthoPediatrics differentiates itself from larger medical device companies by focusing exclusively on pediatric orthopedics, while many competitors repurpose adult implants.
• The company's consistent 20%+ growth rate since inception, excluding 2020, is strong compared to the broader medical device industry.
• The acquisition of Boston Orthotics & Prosthetics allows OrthoPediatrics to compete with companies like Hanger, Inc. in the orthotics and prosthetics market.
• The acquisition of Pega Medical positions OrthoPediatrics to compete with companies like NuVasive and Medtronic in the spinal deformity correction market.
• The company's commitment to clinical education and surgeon training is a key differentiator compared to competitors with less focus on this area.

Stakeholder Impact

• Shareholders can expect continued growth and potential returns on investment.
• Employees may benefit from the company's growth and expansion.
• Customers (surgeons and hospitals) will have access to a broader range of specialized pediatric orthopedic solutions.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's growth and financial performance positively.

Next Steps

• OrthoPediatrics will continue to focus on product development and innovation.
• The company will continue to expand its market reach through strategic acquisitions.
• OrthoPediatrics will continue to invest in clinical education and surgeon training.
• The company will focus on achieving its 2024 revenue and adjusted EBITDA guidance.

Key Dates

Keywords

pediatric orthopedics, orthopedic implants, surgical solutions, scoliosis, trauma, deformity correction, specialty bracing, clinical education, medical devices, acquisitions